Table 1.
Key published studies of repeated hepatic venous pressure gradient (HVPG) measurement in the prevention of variceal rebleeding: total populations and haemodynamic responders (absolute numbers of patients in parentheses)
| Feu15 | Villanueva16 | McCormick17 | Villanueva4 | Patch6 | |
| Total No of patients | 83 | 43* | 63 | 72† | 51‡ |
| % of patients with baseline HVPG measured | 83%(69) | 100%(43) | 89%(56) | 100%(72) | 78%(40) |
| % of patients with remeasurement of HVPG | 83%(69) | 72%(31) | 71%(45)§ | 68%(49) | 35%(18) |
| Time of, or mean interval to, remeasurement (months) | 3 | 3–4 | 5.3 | 1–3 | 2 |
| Child class C | 6%(4) | 16%(7) | 6%(4) | 19%(14) | 47%(24) |
| Alcoholic aetiology | 59%(41) | 51%(25) | 70%(31) | 50%(43) | 63%(32) |
| Follow up (months)(median [range]) | 28 [1–69]** | 18 [4–36] | 22** responders, 26** non-responders [0.1–60] | 20 [1–65] | 8 [0.25–46] |
| Patients with nitrates | 0 | 100%(43) | 68%(30) | 100%(72) | 41%(22) |
| Baseline HVPG (mm Hg)(mean (SD)) | 18.3 (3.6) | 17.7 (3.4) | 17.5 (0.6) responders 18 (1.0) non responders | 19.9 (3.5) | 18.3 (4.9) |
| Haemodynamic responders | 36%(25) | 45%(14) | 64%(28) | 51%(25) | 50%(9) |
| Rebleeding in patients with baseline HVPG measurement | 36%(25) | 26%(11) | 37%(16)¶ | 33%(24) | 37%(19) |
| Mortality in patients with baseline HVPG measurement | 13%(9) | 9%(4) | n/a | 32%(23) | 33%(17) |
*Initial cohort 121 patients, 86 of whom were included (43 for each treatment arm).
†Initial cohort 233 patients, 144 of whom were included (72 for each treatment arm).
‡Initial cohort 205 patients, 102 of whom were included (51 for each treatment arm).
§Only 44 patients included in the study (one patient excluded because of low initial and repeat HVPG (7 mm Hg)).
¶Calculated on the 44 included patients.
**Mean (range).